2025

Kufrin V, Seiler A, Brilloff S, Rothfuß H, Küchler S, Schäfer S, Rahimian E, Baumgarten J, Ding L, Buchholz F, Ball CR, Bornhäuser M, Glimm H, Bill M, Wurm AA. The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers. Cell Death Differ. 2025 Mar 27. doi: 10.1038/s41418-025-01479-7. Epub ahead of print. PMID: 40140561. PubMed

Schönberg PY, Muñoz-Ovalle Á, Paszkowski-Rogacz M, Crespo E, Sürün D, Feldmann A, Buchholz F. A pooled CRISPR screen identifies the Tα2 enhancer element as a driver of TRA expression in a subset of mature human T lymphocytes. Front Immunol. 2025 Mar 14;16:1536003. doi: 10.3389/fimmu.2025.1536003. PMID: 40160815; PMCID: PMC11949936. PubMed

Schwarz FM, Klotz DM, Yang R, Brux M, Buchholz F, Harb H, Link T, Wimberger P, Theis M, Kuhlmann JD (2025). Methylstat sensitizes ovarian cancer cells to PARP-inhibition by targeting the histone demethylases JMJD1B/C. Cancer Gene Ther. 2025 Feb 6. doi: 10.1038/s41417-025-00874-z. Online ahead of print. PubMed